Trial Profile
A study of niraparib in combination with an anti-PD-1 antibody in comparison to standard of care in women with metastatic triple-negative breast cancer in the maintenance setting
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Niraparib (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 03 Apr 2017 New trial record